logo.jpg
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
March 18, 2021 08:30 ET | Helsinn Healthcare S.A.
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
logo.jpg
Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis
April 20, 2020 08:30 ET | Helsinn Healthcare S.A.
Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis Iselin,...
logo.jpg
New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas
February 14, 2020 08:00 ET | Helsinn Healthcare S.A.
New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas Lugano, Switzerland, February 14, 2020 – Helsinn, the Swiss pharmaceutical group focused on...